This Columvi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as the increasing prevalence of cancer worldwide, higher healthcare expenditures, the rise of personalized medicine, expanded insurance coverage, and growing investments in innovative drug delivery technologies.
In the forecast period, growth is expected to be driven by rising consumer demand for eco-friendly products, increasing awareness of health and wellness, growing interest in electric vehicles, higher demand for Internet of Things (IoT) devices, and an increasing appetite for premium and luxury products. Key trends for this period include technological advancements, the adoption of biologic and targeted therapies, personalized medicine, and monoclonal antibody therapies.
The increasing incidence of hematologic malignancies is expected to accelerate the growth of the columvi market in the future. Hematologic malignancies refer to cancers that originate in blood-forming cells, primarily affecting the bone marrow and lymphatic system. The rise in these cancers can be attributed to several factors, including an aging population, increased exposure to carcinogens, lifestyle changes such as obesity, improved detection methods, and geographic variations in incidence rates. Columvi is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) after two or more systemic therapies. For example, in March 2024, the Leukaemia & Lymphoma Society, a US-based professional organization, projected that 187,740 people in the US would be diagnosed with leukemia, lymphoma, or myeloma in 2024. These cases would represent 9.4% of the 2,001,140 total new cancer diagnoses expected in the country. Thus, the growing incidence of hematologic malignancies will drive the growth of the columvi market.
The increasing aging population is expected to drive the growth of the columvi market. The aging population refers to a demographic group with a higher proportion of individuals aged 65 and older, primarily due to increased life expectancy and declining birth rates. The aging population is growing as advancements in healthcare and living standards have extended life expectancy, coupled with declining birth rates in many regions. Columvi offers an effective treatment option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a condition more common among older adults, through targeted and durable therapeutic strategies. For instance, in October 2024, the World Health Organization (WHO) projected that by 2030, one in six people worldwide will be aged 60 or older, with the global population in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and older is expected to double, reaching 2.1 billion, and the population of those aged 80 and older is predicted to triple, growing to 426 million. Therefore, the rising aging population is a key driver of the columvi market’s growth.
A major trend in the columvi market is the development of innovative therapies, such as bispecific T-cell engagers (BiTEs), for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL). BiTEs are engineered proteins that bind both T cells and cancer cells, effectively redirecting the immune system to target and destroy tumor cells. For instance, in June 2023, Roche, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for columvi (glofitamab-gxbm). This approval was for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. The approval was based on positive results from the phase I/II NP30179 study, which evaluated columvi as a fixed-duration therapy over 8.5 months in 132 patients. Among these, 30% had previously undergone CAR T-cell therapy, and 83% were refractory to their most recent treatment. The study showed durable remission, with an overall response rate (ORR) of 56% (74/132) and a complete response (CR) rate of 43% (57/132).
The key company operating in the columvi market is F. Hoffmann-La Roche Ltd.
North America was the largest region in the columvi market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in columvi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the columvi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Columvi (glofitamab-gxbm) is a prescription medication used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have undergone at least two prior treatments. This bispecific monoclonal antibody targets CD20 on B-cells and CD3 on T-cells, enabling an immune response to combat cancer cells. Administered via intravenous infusion, it provides an innovative immunotherapy option for challenging cases of B-cell lymphomas.
The primary indications for columvi include non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). NHL is a cancer that develops in the lymphatic system, which encompasses the lymph nodes, spleen, and bone marrow. Columvi can be utilized as both a bispecific antibody therapeutic and a targeted CD20-CD3 therapy. It is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.
The columvi market research report is one of a series of new reports that provides columvi market statistics, including columvi industry global market size, regional shares, competitors with a columvi market share, detailed columvi market segments, market trends and opportunities, and any further data you may need to thrive in the columvi industry. This columvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The columvi market consists of sales of monoclonal antibodies, bispecific antibodies, small molecule drugs, and diagnostic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as the increasing prevalence of cancer worldwide, higher healthcare expenditures, the rise of personalized medicine, expanded insurance coverage, and growing investments in innovative drug delivery technologies.
In the forecast period, growth is expected to be driven by rising consumer demand for eco-friendly products, increasing awareness of health and wellness, growing interest in electric vehicles, higher demand for Internet of Things (IoT) devices, and an increasing appetite for premium and luxury products. Key trends for this period include technological advancements, the adoption of biologic and targeted therapies, personalized medicine, and monoclonal antibody therapies.
The increasing incidence of hematologic malignancies is expected to accelerate the growth of the columvi market in the future. Hematologic malignancies refer to cancers that originate in blood-forming cells, primarily affecting the bone marrow and lymphatic system. The rise in these cancers can be attributed to several factors, including an aging population, increased exposure to carcinogens, lifestyle changes such as obesity, improved detection methods, and geographic variations in incidence rates. Columvi is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) after two or more systemic therapies. For example, in March 2024, the Leukaemia & Lymphoma Society, a US-based professional organization, projected that 187,740 people in the US would be diagnosed with leukemia, lymphoma, or myeloma in 2024. These cases would represent 9.4% of the 2,001,140 total new cancer diagnoses expected in the country. Thus, the growing incidence of hematologic malignancies will drive the growth of the columvi market.
The increasing aging population is expected to drive the growth of the columvi market. The aging population refers to a demographic group with a higher proportion of individuals aged 65 and older, primarily due to increased life expectancy and declining birth rates. The aging population is growing as advancements in healthcare and living standards have extended life expectancy, coupled with declining birth rates in many regions. Columvi offers an effective treatment option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a condition more common among older adults, through targeted and durable therapeutic strategies. For instance, in October 2024, the World Health Organization (WHO) projected that by 2030, one in six people worldwide will be aged 60 or older, with the global population in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and older is expected to double, reaching 2.1 billion, and the population of those aged 80 and older is predicted to triple, growing to 426 million. Therefore, the rising aging population is a key driver of the columvi market’s growth.
A major trend in the columvi market is the development of innovative therapies, such as bispecific T-cell engagers (BiTEs), for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL). BiTEs are engineered proteins that bind both T cells and cancer cells, effectively redirecting the immune system to target and destroy tumor cells. For instance, in June 2023, Roche, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for columvi (glofitamab-gxbm). This approval was for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. The approval was based on positive results from the phase I/II NP30179 study, which evaluated columvi as a fixed-duration therapy over 8.5 months in 132 patients. Among these, 30% had previously undergone CAR T-cell therapy, and 83% were refractory to their most recent treatment. The study showed durable remission, with an overall response rate (ORR) of 56% (74/132) and a complete response (CR) rate of 43% (57/132).
The key company operating in the columvi market is F. Hoffmann-La Roche Ltd.
North America was the largest region in the columvi market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in columvi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the columvi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Columvi (glofitamab-gxbm) is a prescription medication used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have undergone at least two prior treatments. This bispecific monoclonal antibody targets CD20 on B-cells and CD3 on T-cells, enabling an immune response to combat cancer cells. Administered via intravenous infusion, it provides an innovative immunotherapy option for challenging cases of B-cell lymphomas.
The primary indications for columvi include non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). NHL is a cancer that develops in the lymphatic system, which encompasses the lymph nodes, spleen, and bone marrow. Columvi can be utilized as both a bispecific antibody therapeutic and a targeted CD20-CD3 therapy. It is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.
The columvi market research report is one of a series of new reports that provides columvi market statistics, including columvi industry global market size, regional shares, competitors with a columvi market share, detailed columvi market segments, market trends and opportunities, and any further data you may need to thrive in the columvi industry. This columvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The columvi market consists of sales of monoclonal antibodies, bispecific antibodies, small molecule drugs, and diagnostic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Columvi Market Characteristics4. Columvi Market Trends and Strategies5. Columvi Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Columvi Pricing Analysis & Forecasts30. Global Columvi Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Columvi Market32. Recent Developments in the Columvi Market
3. Columvi Market Biologic Drug Characteristics
6. Global Columvi Growth Analysis and Strategic Analysis Framework
8. Columvi Market Segmentation
9. Global Columvi Epidemiology of Clinical Indications
10. Columvi Market Regional and Country Analysis
11. Asia-Pacific Columvi Market
12. China Columvi Market
13. India Columvi Market
14. Japan Columvi Market
15. Australia Columvi Market
16. South Korea Columvi Market
17. Western Europe Columvi Market
18. UK Columvi Market
19. Germany Columvi Market
20. France Columvi Market
21. Eastern Europe Columvi Market
22. North America Columvi Market
23. USA Columvi Market
24. Canada Columvi Market
25. South America Columvi Market
26. Middle East Columvi Market
27. Africa Columvi Market
28. Columvi Market Competitive Landscape and Company Profiles
29. Global Columvi Market Pipeline Analysis
33. Columvi Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Columvi Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on columvi market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for columvi? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The columvi market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Non-Hodgkin Lymphoma (NHL); Chronic lymphocytic Leukemia (CLL)2) by Mechanism: Bispecific Antibody Therapeutics; Targeted CD20-CD3 Therapies
3) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies
Key Companies Mentioned: F. Hoffmann-La Roche Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
